{"id":"W2403219295","doi":"10.1158/1538-7445.sabcs15-s6-01","title":"Abstract S6-01: <i>PIK3CA</i> status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":88,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Fulvestrant; Clinical endpoint; Internal medicine; Oncology; Population; Breast cancer; Cancer; Metastatic breast cancer; Everolimus; Clinical trial; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Estrogen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00152362,0.000407079,0.0008574863,0.0001623898,0.0002351304,0.00006308277,0.000614036,0.0001441299,0.0001274709],"category_scores_gemma":[0.0009845011,0.0002625676,0.0001153315,0.000463833,0.0006879587,0.00003274833,0.0003370946,0.0004603874,0.000002427988],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008272932,"about_ca_system_score_gemma":0.002341961,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.03491305,"about_ca_topic_score_gemma":0.02740828,"domain_scores_codex":[0.9954115,0.0003318659,0.001114157,0.001016863,0.0007781493,0.001347472],"domain_scores_gemma":[0.9962989,0.001784398,0.0004031682,0.0008670912,0.000320497,0.0003259127],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7080078,0.0004337764,0.0004689102,0.0000541232,0.0001871164,0.0001222525,0.0008871435,0.002037893,0.2827207,0.00002249437,0.000339998,0.004717882],"study_design_scores_gemma":[0.931865,0.001791872,0.0110074,0.001099865,0.00005585483,0.000009800485,0.0007167295,0.00007935886,0.04840799,0.00007380711,0.004309613,0.0005826716],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9874603,0.002844491,0.00001835049,0.001310173,0.0002644189,0.002758535,0.005132455,0.00001240094,0.0001988757],"genre_scores_gemma":[0.992197,0.005335468,0.00004180861,0.00009766818,0.0006693087,0.001355467,0.0001615771,0.00007555774,0.00006610675],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2343127,"threshold_uncertainty_score":0.9999827,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02083531772490217,"score_gpt":0.321575235329682,"score_spread":0.3007399176047799,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}